ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 396

Clinical, Physiologic, and Radiologic Features Associated with Severe MDA5-Associated Interstitial Lung Disease

Tracy Doyle1, Priya Borker2, Elaine Fletcher1, David Murphy3, Rachna Madan3 and Paul F. Dellaripa4, 1Brigham and Women's Hospital, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA, 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: interstitial lung disease and myositis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Autoantibodies against melanoma differentiation-associated protein 5 (MDA-5) have been described in patients with dermatomyositis (DM) and progressive interstitial lung disease (ILD). Previous cohorts have shown a significant portion of these patients can develop rapidly progressive ILD. The goal of our study is to describe the phenotypic, physiologic, and radiologic features of this cohort and to identify important factors that may predict prognosis in terms of disease severity and outcomes.

Methods: A retrospective single center observational longitudinal study characterized clinical characteristics, lung function, HRCT findings, and outcomes of MDA5-positive patients referred to a tertiary hospital. Patients who met the following criteria were defined as severe ILD: (1) baseline FVC <50% with ILD as known cause; (2) oxygen use due to ILD; (3) lung transplant evaluation due to ILD; (4) respiratory failure requiring mechanical ventilation for ILD; (5) death due to ILD or MDA5 diagnosis. CT scans were reviewed by 2 radiologists to determine ILD pattern and a semi-quantitative CT severity score.

Results: Fifteen MDA5-positive cases were identified between 2007 to 2018; 4 (27%) had clinically amyopathic DM (CADM), 6 (40%) had vasculopathic skin lesions, and 3 (20%) had both CADM/vasculopathy. Seven subjects (47%) developed severe ILD, of which 3 died from hypoxemic respiratory failure and 1 from failure to thrive. Those with severe disease had lower FVC%, TLC%, DLCO%, and CT ILD score at baseline and 1 year of following up, and were more likely to have a cryptogenic organizing pattern on CT. Smoking history, myositis, oral ulcers, nasal congestion, pneumomediastinum, and higher levels of inflammatory markers were more likely to be found in the severe group, whereas Raynaud’s phenomenon and non-specific interstitial pneumonia pattern on CT were more common in the mild/moderate group.

Conclusion: Our data supports that MDA5Ab-associated ILD seems to follow a bimodal pattern, which can be severe and/or progressive in a significant number of cases, but may be treatable and stabilized in certain patients. Although CADM and ulcerative and nodular lesions consistent with vasculopathy were found in equal frequency in the entire cohort and in the severe ILD subgroup, risk factors for severe disease appear to be smoking history, myositis, oral ulcers, nasal congestion, pneumomediastinum, and higher levels of inflammatory markers.

MDA-5 = melanoma differentiation–associated gene 5; CADM = clinically amyopathic dermatomyositis; ILD = interstitial lung disease


Disclosure: T. Doyle, None; P. Borker, None; E. Fletcher, None; D. Murphy, None; R. Madan, None; P. F. Dellaripa, up to date, 7,Genentech, Inc., 9.

To cite this abstract in AMA style:

Doyle T, Borker P, Fletcher E, Murphy D, Madan R, Dellaripa PF. Clinical, Physiologic, and Radiologic Features Associated with Severe MDA5-Associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/clinical-physiologic-and-radiologic-features-associated-with-severe-mda5-associated-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-physiologic-and-radiologic-features-associated-with-severe-mda5-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology